{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:42:27Z","timestamp":1790379747477,"version":"4.1.0"},"reference-count":48,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000098","name":"NIH Clinical Center","doi-asserted-by":"publisher","award":["UG1DA015831"],"award-info":[{"award-number":["UG1DA015831"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Academic Emergency Medicine"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As the opioid overdose epidemic escalates, there is an urgent need for treatment innovations to address both patient and clinician barriers when initiating buprenorphine in the emergency department (ED). These include insurance status, logistical challenges such as the ability to fill a prescription and transportation, concerns regarding diversion, and availability of urgent referral sites. Extended\u2010release buprenorphine (XR\u2010BUP) preparations such as a new 7\u2010day injectable could potentially solve some of these issues. We describe the pharmacokinetics of a new 7\u2010day XR\u2010BUP formulation and the feasibility of its use in the ED setting. We report our early experiences with this medication (investigational drug CAM2038), in the context of an ongoing clinical trial entitled Emergency Department\u2010Initiated BUP VAlidaTION (ED INNOVATION), to inform emergency clinicians as they consider incorporating this medication into their practice. The medication was approved by the European Medicines Agency in 2018 and the U.S. Food and Drug Administration in 2023 for those 18\u2009years or older for the treatment of moderate to severe opioid use disorder (OUD). We report our experience with approximately 800 ED patients with OUD who received the 7\u2010day XR\u2010BUP preparation in the ED between June 2020 and July 2023.<\/jats:p>","DOI":"10.1111\/acem.14782","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T07:58:35Z","timestamp":1690531115000},"page":"1264-1271","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Early emergency department experience with 7\u2010day <scp>extended\u2010release<\/scp> injectable buprenorphine for opioid use disorder"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3833-1871","authenticated-orcid":false,"given":"Gail","family":"D'Onofrio","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine Yale School of Medicine  New Haven Connecticut USA"},{"name":"Yale School of Public Health  New Haven Connecticut USA"},{"name":"Department of Internal Medicine Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanmarie","family":"Perrone","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Perelman School of Medicine at the University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-5945","authenticated-orcid":false,"given":"Kathryn F.","family":"Hawk","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Yale School of Medicine  New Haven Connecticut USA"},{"name":"Yale School of Public Health  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7276-0549","authenticated-orcid":false,"given":"Ethan","family":"Cowan","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"McCormack","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine NYU Langone Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5460-5732","authenticated-orcid":false,"suffix":"Jr.","given":"Edouard","family":"Coupet","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia H.","family":"Owens","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shara H.","family":"Martel","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Huntley","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse  Rockville Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Center on Drug and Alcohol Research University of Kentucky College of Medicine  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Lofwall","sequence":"additional","affiliation":[{"name":"Center on Drug and Alcohol Research University of Kentucky College of Medicine  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Herring","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Highland Hospital Oakland  Oakland California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ED\u2010INNOVATION Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-00880-7"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1212"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1811988"},{"key":"e_1_2_10_5_1","unstructured":"Public Use Data File Documentation. Centers for Disease Control and Prevention NCHS National Vital Statistics System. 2015\u20132021. Accessed May 23 2023.https:\/\/www.cdc.gov\/nchs\/nvss\/mortality_public_use_data.htm"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6913a3"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-3107"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2019.04.020"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3474"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.21209"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109933"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002969"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2019.11.44382"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/acem.14369"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.4561"},{"key":"e_1_2_10_16_1","unstructured":"Office of the Secretary Department of Health and Human Service.Practice Guidelines for the Administration of Buprenorphine for treating Opioid Use Disorder. Federal Register April 26 2021."},{"key":"e_1_2_10_17_1","unstructured":"Elimination of the DATA waiver program. U.S. Department of Justice Drug Enforcement Administration Diversion Control Division.December 29 2022. Accessed July 21 2023.https:\/\/www.deadiversion.usdoj.gov\/pubs\/docs\/dear_registrant_AM_01122023.html"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.5038"},{"key":"e_1_2_10_19_1","unstructured":"FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder Press release. Food and Drug Administration. May 23 2023. Accessed June 01 2023.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010new\u2010buprenorphine\u2010treatment\u2010option\u2010opioid\u2010use\u2010disorder"},{"key":"e_1_2_10_20_1","unstructured":"Press Release. Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US. Camurus AB. 2021. Accessed June 01 2023.https:\/\/www.prnewswire.com\/news\u2010releases\/camurus\u2010announces\u2010pdufa\u2010date\u2010for\u2010brixadi\u2010for\u2010the\u2010treatment\u2010of\u2010opioid\u2010use\u2010disorder\u2010in\u2010the\u2010us\u2010301320571.html"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106359"},{"key":"e_1_2_10_22_1","first-page":"113","volume-title":"Buprenorphine: Combating Drug Abuse with a Unique Opioid","author":"Walter DS","year":"1995"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00058-9"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.159"},{"key":"e_1_2_10_25_1","unstructured":"JonesRT MendelsonJ UptonR.An open\u2010label partially blinded balanced 4 \u00d7 4 latin square crossover study to evaluate the pharmacokinetic and dose\u2010proportionality of buprenorphine when administered in sublingual tablets alone or in combination with naloxone in nondependent opiate users. NIDA Contract N01DA\u20104\u20138306 Report Pharmacokinetic and Pharmacodynamic Studies for Medication Development.1997."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13018"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108764"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14636"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1874"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.07.035"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0155-0"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0472-9"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.04.008"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1052"},{"key":"e_1_2_10_35_1","unstructured":"U.S. District Court Orders FDA to Reconsider Application for Final Approval of BRIXADI\u2122 (buprenorphine) Extended\u2010Release Injection for the Treatment of Opioid Use Disorder. Braeburn. 2019.https:\/\/braeburnrx.com\/u\u2010s\u2010district\u2010court\u2010orders\u2010fda\u2010to\u2010reconsider\u2010braeburns\u2010application\u2010for\u2010final\u2010approval\/"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2003.10400007"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2021.09.210"},{"key":"e_1_2_10_38_1","unstructured":"Brixadi Prescribing Information Package Insert. Reference ID: 5178299. Braeburn Inc May 2023."},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2002908"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.09.003"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13069"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.04.006"},{"key":"e_1_2_10_43_1","volume-title":"The ASAM Criteria. Treatment Criteria for Addictive, Substance\u2010Related, and Co\u2010Occurring Conditions","author":"Mee\u2010Lee D","year":"2013"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.6108"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000929"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmab073"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.17128"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2018.1546862"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20220456"}],"container-title":["Academic Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acem.14782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T10:39:23Z","timestamp":1703673563000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acem.14782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1111\/acem.14782"],"URL":"https:\/\/doi.org\/10.1111\/acem.14782","archive":["Portico"],"relation":{},"ISSN":["1069-6563","1553-2712"],"issn-type":[{"value":"1069-6563","type":"print"},{"value":"1553-2712","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]},"assertion":[{"value":"2023-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}